Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.
April 1, 2021
By: NEIL KELLY
What has changed during the pandemic? Pharma companies currently face many opportunities. Increased profits are one result of the continued surge in demand from Covid-19 related activities. Investors are now pushing CEOs and their leadership teams to reveal their road maps for the future. That is, how they will best utilize the current business environment and maintain momentum for further sustainable growth. For leadership teams today, linking business strategy, organizational design and operational delivery will create the path to success, driven by people. The pharma industry has seen a surge in organizations deciding to act fast on acquisitions that they have long been exploring and moving quickly to finalize in 2020/21 fiscal years. Those acquisitions have been driven by the need to service the demand requests from customers, particularly vaccine manufacturing capacity. Organizations who are taking on new facilities and don’t have a well-oiled mergers and acquisitions (M&A) talent strategy, can find themselves quickly stuck with many challenges, for both the purchaser and acquirer. Throw in a pandemic and this magnifies issues. Competition among contract development and manufacturing organizations (CDMOs) has increased exponentially due to a number of factors driven by smart investors, demand, Big Pharma refocusing and a sharp increase in new innovative molecules hitting the market. The pandemic has significantly pushed this demand for even more capacity, which is set to continue. A less publicized impact from increased competition is the impact on talent. The availability of talent in the market has been significantly strained, and now stands at a critical point in some geographical regions. In order to demonstrate this point, Big Pharma managed to hire talent mostly through strong internal talent development programs historically. New technologies, digitalization and innovation are creating the perfect storm for organizations to navigate, requiring a rapid rethink of how they hire and develop the next generation of employees, which is driving greater levels of external hiring. Aftershocks of Covid-19 on talent supply chain The pandemic is now compounding the talent issue. As organizations accelerate their expansion plans, growth plans are often not aligned to the available external workforce. The greatest operational impact has been felt by the pharma manufacturing sites, where the employee cannot be based remotely, as they are part of the production at a specific location. These sites were hit the hardest in those areas, who experienced the highest levels of Covid infections, which required smart planning on behalf of those leadership teams. One key outcome has been of organizations to think about how and where work gets done, some organizations are insisting all employees needs to be back on site, while others are maintaining remote working as benefit to the employee. Mobility of talent of has been impacted throughout this pandemic, with less people physically being able to move through country restrictions. Although what is unclear is the longer-term impact of talent mobility across the globe, mostly driven by country specific restrictions, candidate behaviors and potentially unwillingness to move. Early studies suggest that people travelling much less will be a trend that may continue, resulting in more hyperlocal mobility and even less talent considering a relocation. This trend is forcing sites and companies to think differently, considering things like ‘virtual assignments’, staying in the home location, while working in the same time zone where the work is being delivered. Impact to organizational design, talent and recruitment costs Many organizations who are on a growth journey, are trying to facilitate this growth with a business model that is localized. Most organizations have a collection of smaller P&L’s from country legal entities, which are often a result of legacy acquisitions. Many organizations opt for fewer resources that sit in the ‘center’. The decision of the operating model creates an impact to an organization’s ability to hire the right talent in an effective and sustainable way to drive their growth, as they often are unable to easily leverage expertise, resources and internal talent. As a result of this structure, many organizations will have a patchwork of how they attract and develop talent; those bigger organizations are leveraging their scale, while a smaller sites may suffer. This model becomes very exposed when talent dries up locally, requiring them to go outside of commutable distance. This often results in leadership to start taking knee jerk decisions on hiring, often resulting in chaotic costly decision when managing recruitment agencies, throwing more and more investment to deal with the challenge. Although rarely organizations stop to ask the question if there is another way to manage talent resources more effectively, building the availability of talent into an organization’s investment decisions, leveraging more sophisticated market and talent insights. Finding your purpose and power of employer brand Many organizations in pharma often underplay their role in people’s lives, often as a symptom of operating in a highly regulated environment, historically have opted for a more conservative approach to branding. In other cases, they struggle to establish an employer brand, often citing that it is too expensive and no possible return on investment, as they are a business-to-business service offering. Through Covid-19 all organizations minds were quickly focused on their purpose and the CDMO market thrust into the limelight. Since most CDMO companies never even had a structured communications plan, let alone an employer brand, never would have anyone guessed that this highly unusual situation would expose this frailty. Big Pharma was able to do better than CDMOs overall, because they had the infrastructure to handle the surge in communications. Although what was surprising was the role that the employer brand teams played through this crisis, often followers of these companies tracked news through social media channels, historically used for recruitment branding. This gave a compelling reason for marketing and employer brand to work collaboratively, demonstrating how crucial the need to integrate messaging is to the external market and the key role employer branding can play in your organization. Building an employer brand requires a very specific skill set, although has many advantages. Here are the top 5 reasons why every organization needs to build an integrated employer brand:
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !